Published in Thromb Haemost on October 01, 2001
Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev (2009) 1.62
Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol (2001) 1.19
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population. Hum Genet (2005) 0.85
Fetal gene defects precipitate platelet-mediated pregnancy failure in factor V Leiden mothers. J Exp Med (2007) 0.84
Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. Arterioscler Thromb Vasc Biol (2013) 0.81
A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARe) Consortium. Hum Mol Genet (2011) 0.81
Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol (2008) 0.79
The endothelial cell protein C receptor: a candidate genetic risk factor for thrombosis. Thromb Haemost (2001) 0.75
Endothelial Protein C Receptor gene Expression in a Female with Homozygous EPCR gene 23-bp Insertion. Turk J Haematol (2012) 0.75
Role of leptin in the neuroendocrine response to fasting. Nature (1996) 8.02
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med (2001) 4.10
Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A (1981) 3.88
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem (1982) 3.51
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta (1979) 2.83
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost (2005) 2.70
The regulation of natural anticoagulant pathways. Science (1987) 2.58
The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A (1996) 2.58
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem (1994) 2.52
Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost (2011) 2.51
Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A (1986) 2.43
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem (1979) 2.21
The conversion of prothrombin to thrombin. I. Characterization of the reaction products formed during the activation of bovine prothrombin. J Biol Chem (1974) 2.19
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem (1991) 2.14
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
The interaction of a Ca2+-dependent monoclonal antibody with the protein C activation peptide region. Evidence for obligatory Ca2+ binding to both antigen and antibody. J Biol Chem (1988) 2.06
Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem (1982) 2.04
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med (1984) 1.98
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem (1981) 1.94
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem (1988) 1.88
Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest (1984) 1.84
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation (1997) 1.81
The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood (2000) 1.80
Proteolytic formation and properties of gamma-carboxyglutamic acid-domainless protein C. J Biol Chem (1983) 1.77
Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem (1994) 1.77
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Significance of ST-segment elevation during dobutamine-stress echocardiography in patients with acute myocardial infarction treated with thrombolysis. Eur Heart J (1996) 1.75
Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest (1987) 1.74
Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost (2007) 1.73
A new carboxylation reaction. The vitamin K-dependent incorporation of H-14-CO3- into prothrombin. J Biol Chem (1975) 1.71
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost (2003) 1.67
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
A polypeptide region of bovine prothrombin specific for binding to phospholipids. Proc Natl Acad Sci U S A (1973) 1.65
A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem (1976) 1.64
Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood (1989) 1.64
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem (1989) 1.63
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost (1991) 1.59
Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem (1990) 1.59
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury. Thorax (2008) 1.58
Interaction between photosystem I and ferredoxin. Identification by chemical cross-linking of the polypeptide which binds ferredoxin. Eur J Biochem (1987) 1.58
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J Biol Chem (1996) 1.56
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem (2000) 1.54
Vitamin K-dependent carboxylase. Requirements of the rat liver microsomal enzyme system. J Biol Chem (1976) 1.53
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Diabetes (1996) 1.53
Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood (2001) 1.51
Activated protein C inhibits platelet prothrombin-converting activity. Blood (1979) 1.51
Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation (1991) 1.50
Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest (1981) 1.50
The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem (1992) 1.50
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost (2000) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci U S A (1991) 1.46
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
The active site of thrombin is altered upon binding to thrombomodulin. Two distinct structural changes are detected by fluorescence, but only one correlates with protein C activation. J Biol Chem (1991) 1.44
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41